Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma

Yun Yen, Samuel So, Michal Rose, M. Wasif Saif, Edward Chu, Shwu Huey Liu, Angeline Foo, Zaoli Jiang, Tahmun Su, Yung Chi Cheng

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (165 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.

Original languageEnglish
Pages (from-to)4083-4092
Number of pages10
JournalAnticancer Research
Volume29
Issue number10
Publication statusPublished - Oct 1 2009
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Therapeutics
Survival
Liver Neoplasms
Heterografts
Quality of Life
Medicine
Capecitabine
PHY 906
Population

Keywords

  • Adjuvant therapy
  • Capecitabine
  • Hepatocellular carcinoma (HCC)
  • Phase I/II
  • PHY906

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Yen, Y., So, S., Rose, M., Saif, M. W., Chu, E., Liu, S. H., ... Cheng, Y. C. (2009). Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Research, 29(10), 4083-4092.

Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. / Yen, Yun; So, Samuel; Rose, Michal; Saif, M. Wasif; Chu, Edward; Liu, Shwu Huey; Foo, Angeline; Jiang, Zaoli; Su, Tahmun; Cheng, Yung Chi.

In: Anticancer Research, Vol. 29, No. 10, 01.10.2009, p. 4083-4092.

Research output: Contribution to journalArticle

Yen, Y, So, S, Rose, M, Saif, MW, Chu, E, Liu, SH, Foo, A, Jiang, Z, Su, T & Cheng, YC 2009, 'Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma', Anticancer Research, vol. 29, no. 10, pp. 4083-4092.
Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH et al. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Research. 2009 Oct 1;29(10):4083-4092.
Yen, Yun ; So, Samuel ; Rose, Michal ; Saif, M. Wasif ; Chu, Edward ; Liu, Shwu Huey ; Foo, Angeline ; Jiang, Zaoli ; Su, Tahmun ; Cheng, Yung Chi. / Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. In: Anticancer Research. 2009 ; Vol. 29, No. 10. pp. 4083-4092.
@article{c515d279deaa43f5ab6c26531b414d77,
title = "Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma",
abstract = "PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60{\%} of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (165 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.",
keywords = "Adjuvant therapy, Capecitabine, Hepatocellular carcinoma (HCC), Phase I/II, PHY906",
author = "Yun Yen and Samuel So and Michal Rose and Saif, {M. Wasif} and Edward Chu and Liu, {Shwu Huey} and Angeline Foo and Zaoli Jiang and Tahmun Su and Cheng, {Yung Chi}",
year = "2009",
month = "10",
day = "1",
language = "English",
volume = "29",
pages = "4083--4092",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma

AU - Yen, Yun

AU - So, Samuel

AU - Rose, Michal

AU - Saif, M. Wasif

AU - Chu, Edward

AU - Liu, Shwu Huey

AU - Foo, Angeline

AU - Jiang, Zaoli

AU - Su, Tahmun

AU - Cheng, Yung Chi

PY - 2009/10/1

Y1 - 2009/10/1

N2 - PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (165 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.

AB - PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (165 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.

KW - Adjuvant therapy

KW - Capecitabine

KW - Hepatocellular carcinoma (HCC)

KW - Phase I/II

KW - PHY906

UR - http://www.scopus.com/inward/record.url?scp=71949107671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71949107671&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 4083

EP - 4092

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -